DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Clark SF. Iron deficiency anemia: Diagnosis and management.
Curr Opin Gastroenterol, 2009, 25:122–128.
Conrad ME, Umbreit JN. Pathways of iron absorption. Blood
Cells Mol Dis, 2002, 29:336–355.
Crawford J. Neutrophil growth factors. Curr Hematol Rep, 2002,
1:95–102.
Dallman PR. Manifestations of iron deficiency. Semin Hematol,
1982, 19:19–30.
Dallman PR, Siimes MA, Stekel A. Iron deficiency in infancy
and childhood. Am J Clin Nutr, 1980, 33:86–118.
de Bie P, Muller P, Wijmenga C, Klomp LW. Molecular pathogenesis
of Wilson and Menkes disease: correlation of mutations
with molecular defects and disease phenotypes. J Med
Genet, 2007, 44:673–688.
De Domenico I, Nemeth E, Nelson JM, et al. The hepcidin-binding
site on ferroportin is evolutionarily conserved. Cell Metab,
2008, 8:146–156.
Du XX, Williams DA. Interleukin-11: A multifunctional growth
factor derived from the hematopoietic microenvironment.
Blood, 1994, 83:2023–2030.
Dunlap WM, James GW 3rd, Hume DM. Anemia and neutropenia
caused by copper deficiency. Ann Intern Med, 1974,
80:470–476.
Eichner ER, Hillman RS. Effect of alcohol on serum folate level.
J Clin Invest, 1973, 52:584–591.
Eschbach JW, Egrie JC, Downing MR, et al. Correction of the
anemia of end-stage renal disease with recombinant human
erythropoietin. Results of a combined phase I and II clinical
trial. N Engl J Med, 1987, 316:73–78.
Faich G, Strobos J. Sodium ferric gluconate complex in sucrose:
Safer intravenous iron therapy than iron dextrans. Am J Kidney
Dis, 1999, 33:464–470.
Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like
gene is mutated in patients with hereditary haemochromatosis.
Nat Genet, 1996, 13:399–408.
Fernandez-Banares F, Monzon H, Forne M. A short review of
malabsorption and anemia. World J Gastroenterol, 2009,
15:4644–4652.
Fibbe WE, Heemskerk DP, Laterveer L, et al. Accelerated
reconstitution of platelets and erythrocytes after syngeneic
transplantation of bone marrow cells derived from thrombopoietin
pretreated donor mice. Blood, 1995, 86:
3308–3313.
Finberg KE. Iron-refractory iron deficiency anemia. Semin
Hematol, 2009, 46:378–386.
Finch CA, Huebers H. Perspectives in iron metabolism. N Engl
J Med, 1982, 306:1520–1528.
Fischl M, Galpin JE, Levine JD, et al. Recombinant human erythropoietin
for patients with AIDS treated with zidovudine.
N Engl J Med, 1990, 322:1488–1493.
Galy B, Ferring-Appel D, Kaden S, et al. Iron regulatory proteins
are essential for intestinal function and control key iron
absorption molecules in the duodenum. Cell Metab, 2008,
7:79–85.
Gambling L, Andersen HS, McArdle HJ. Iron and copper, and
their interactions during development. Biochem Soc Trans,
2008, 36:1258–1261.
Ganz T. Hepcidin, a key regulator of iron metabolism and mediator
of anemia of inflammation. Blood, 2003, 102:783–788.
Ganz T. Iron homeostasis: Fitting the puzzle pieces together. Cell
Metab, 2003, 7:288–290.
Ganz T, Nemeth E. Iron sequestration and anemia of inflammation.
Semin Hematol, 2009, 46:387–393.
Garrick MD, Garrick LM. Cellular iron transport. Biochim
Biophys Acta, 2009, 1790:309–325.
Gerhartz HH, Engelhard M, Meusers P, et al. Randomized,
double-blind, placebo-controlled, phase III study of recombinant
human granulocyte-macrophage colony-stimulating factor
as adjunct to induction treatment of high-grade malignant
non-Hodgkin’s lymphomas. Blood, 1993, 82:2329–2339.
Goodnough LT, Rudnick S, Price TH, et al. Increased preoperative
collection of autologous blood with recombinant human
erythropoietin therapy. N Engl J Med, 1989, 321:1163–1168.
Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and
erythropoiesis. Blood, 2000, 96:823–833.
Goodwin RG, Lupton S, Schmierer A, et al. Human interleukin
7: molecular cloning and growth factor activity on human and
murine B-lineage cells. Proc Natl Acad Sci USA, 1989,
86:302–306.
Gough NM, Gough J, Metcalf D, et al. Molecular cloning of
cDNA encoding a murine hematopoietic growth regulator,
granulocyte-macrophage colony stimulating factor. Nature,
1984, 309:763–767.
Gordeuk VR, Sergueeva AI, Miasnikova GY, et al. Congenital
disorder of oxygen sensing: Association of the homozygous
Chuvash polycythemia VHL mutation with thrombosis and
vascular abnormalities but not tumors. Blood, 2004,
103:3924–3932.
Grabstein KH, Eisenman J, Shanebeck K, et al. Cloning of a T
cell growth factor that interacts with the β chain of the interleukin-2
receptor. Science, 1994, 264:965–968.
Graham GG, Cordano A. Copper deficiency in human subjects.
In: Trace Elements in Human Health and Diseases, Zinc and
Copper, Academic Press, New York, 1976.
Grebe G, Martinez-Torres C, Layrisse M. Effect of meals and ascorbic
acid on the absorption of a therapeutic dose of iron as ferrous
and ferric salts. Curr Ther Res Clin Exp, 1975, 17:382–397.
Green R, Miller JW. Folate deficiency beyond megaloblastic anemia:
Hyperhomocysteinemia and other manifestations of dysfunctional
folate status. Semin Hematol, 1999, 36:47–64.
Haas R, Ho AD, Bredthauer U, et al. Successful autologous
transplantation of blood stem cells mobilized with recombinant
human granulocyte-macrophage colony-stimulating
factor. Exp Hematol, 1990, 18:94–98.
Hahn PF. The use of radioactive isotopes in the study of iron and
hemoglobin metabolism and the physiology of the erythrocyte.
Adv Biol Med Phys, 1948, 1 (1 vol.):287–319.
Hakami N, Neiman PE, Canellos GP, Lazerson J. Neonatal
megaloblastic anemia due to inherited transcobalamin II deficiency
in two siblings. N Engl J Med, 1971, 285:1163–1170.
Hammond WPT, Price TH, Souza LM, Dale DC. Treatment of
cyclic neutropenia with granulocyte colony-stimulating factor.
N Engl J Med, 1989, 320:1306–1311.
Harker LA. Physiology and clinical applications of platelet
growth factors. Curr Opin Hematol, 1999, 6:127–134.
Hayat A. Safety issues with intravenous iron products in the
management of anemia in chronic kidney disease. Clin Med
Res, 2008, 6:93–102.
Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head
and neck cancer patients with anaemia undergoing radiotherapy:
Randomised, double-blind, placebo-controlled trial.
Lancet, 2003, 362:1255–1260.
1097
CHAPTER 37
HEMATOPOIETIC AGENTS